247 related articles for article (PubMed ID: 29023824)
1. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
[TBL] [Abstract][Full Text] [Related]
2. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
3. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
6. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
7. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
9. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
10. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
[TBL] [Abstract][Full Text] [Related]
11. TGR5 in the Cholangiociliopathies.
Masyuk TV; Masyuk AI; LaRusso NF
Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Gradilone SA; Habringer S; Masyuk TV; Howard BN; Masyuk AI; Larusso NF
Am J Pathol; 2014 Mar; 184(3):600-8. PubMed ID: 24434010
[TBL] [Abstract][Full Text] [Related]
13. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
[No Abstract] [Full Text] [Related]
14. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
[TBL] [Abstract][Full Text] [Related]
16. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.
Santos-Laso A; Izquierdo-Sanchez L; Rodrigues PM; Huang BQ; Azkargorta M; Lapitz A; Munoz-Garrido P; Arbelaiz A; Caballero-Camino FJ; Fernández-Barrena MG; Jimenez-Agüero R; Argemi J; Aragon T; Elortza F; Marzioni M; Drenth JPH; LaRusso NF; Bujanda L; Perugorria MJ; Banales JM
Liver Int; 2020 Jul; 40(7):1670-1685. PubMed ID: 32378324
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
Ji R; Chen J; Xie Y; Dou X; Qing B; Liu Z; Lu Y; Dang L; Zhu X; Sun Y; Zheng X; Zhang L; Guo D; Chen Y
J Hepatol; 2023 Apr; 78(4):754-769. PubMed ID: 36681161
[TBL] [Abstract][Full Text] [Related]
18. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
[TBL] [Abstract][Full Text] [Related]
19. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
[TBL] [Abstract][Full Text] [Related]
20. Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins.
Masyuk AI; Masyuk TV; Trussoni CE; Pirius NE; LaRusso NF
Hepatology; 2022 May; 75(5):1110-1122. PubMed ID: 34942041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
